Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.

NCT05691244 is registered in ClinicalTrials.gov with Pharmazz, Inc. as lead sponsor.

NCT NCT05691244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05691244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.
Lead sponsor
Pharmazz, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
July 24, 2025
Completion date
December 31, 2027
Enrollment
514 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke, cerebral stroke